TokenPost·
Myriad Genetics Raises 2026 Revenue Outlook Midpoint to $785 Million
The company set a range of $780 million to $790 million as higher revenue per test partly offsets expected Prenatal Health softness.
More news
- TokenPostCrypto-Linked U.S. Stocks Slide, With Circle and BitMine Near 10% Losses
- Crypto BriefingArm Holdings posts record quarter, sets $15 billion AGI CPU revenue target for 2031
- TokenPostCircle Freezes $1.1 Billion in USDC Tied to Binance Exploit
- TokenPostU.S. Energy Efforts Lower Gas Shortage Risk, But Oil Swings Persist
- TokenPostGromaCorp Deploys Real Estate Issuance and Redemptions on Uniswap
- TokenPostPutin Places Four Japan Tobacco Units in Russia Under Temporary Management